Related Posts
- BET Inhibitor BMS‑986158 for MF: Phase I/II Trial Results
KEY TAKEAWAYS The phase I/II trial aimed to evaluate the efficacy and safety of BMS-986158,…
Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy